Back to Search Start Over

Supplementary Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....967fa8306079a83994166b6b61468dab
Full Text :
https://doi.org/10.1158/1078-0432.22481009